Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate

Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate Publisher Pubmed

Javadian N¹ ; Magrouni H¹ ; Ghaffarpour M¹ ; Ranjiburachaloo S¹

Show Affiliations

1. Department of Neurology, Imam Khomeini Hospital, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Clinical Neuropharmacology Published:2021

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system, characterized by a specific antibody that selectively binds aquaporin-4 channel. This is a report of an NMOSD case, with severe attacks of optic neuritis and myelitis after initiate of dimethyl fumarate (DMF). We suggested that DMF could deteriorate the neuromyelitis optica (NMO) disease course, which results in serious morbidity and mortality in patients. Thus, initiation of DMF should be avoided before ruling out NMOSD in patients experiencing demyelinating attacks, especially in the case of recurrent optic neuritis or myelopathy and concurrency of other rheumatologic diseases. © Wolters Kluwer Health, Inc. All rights reserved.

2. Optic Neuritis With Radiological Longitudinal Spinal Cord Involvement and Seronegative Anti-Aquaporin Antibody: Evidence From a Case Study, Multiple Sclerosis and Related Disorders (2017)

Experts (# of related papers)

Abdolreaza Naser Moghadasi (2)

Mohammad Ali Sahraian (1)

Style	Citing Format
MLA	Javadian N, et al.. "Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate." Clinical Neuropharmacology, vol. 44, no. 1, 2021, pp. 21-22.
APA	Javadian N, Magrouni H, Ghaffarpour M, Ranjiburachaloo S (2021). Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate. Clinical Neuropharmacology, 44(1), 21-22.
Chicago	Javadian N, Magrouni H, Ghaffarpour M, Ranjiburachaloo S. "Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate." Clinical Neuropharmacology 44, no. 1 (2021): 21-22.
Harvard	Javadian N et al. (2021) 'Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate', Clinical Neuropharmacology, 44(1), pp. 21-22.
Vancouver	Javadian N, Magrouni H, Ghaffarpour M, Ranjiburachaloo S. Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate. Clinical Neuropharmacology. 2021;44(1):21-22.
BibTex	@article{ author = {Javadian N and Magrouni H and Ghaffarpour M and Ranjiburachaloo S}, title = {Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate}, journal = {Clinical Neuropharmacology}, volume = {44}, number = {1}, pages = {21-22}, year = {2021} }
RIS	TY - JOUR AU - Javadian N AU - Magrouni H AU - Ghaffarpour M AU - Ranjiburachaloo S TI - Severe Relapses of Neuromyelitis Optica Spectrum Disorder During Treatment With Dimethyl Fumarate JO - Clinical Neuropharmacology VL - 44 IS - 1 SP - 21 EP - 22 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract